Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products

This article was originally published in The Tan Sheet

Executive Summary

Unapproved, single-ingredient guaifenesin extended-release Rx products should no longer be marketed because there is now an approved OTC version, according to FDA
Advertisement

Related Content

FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
Adams Hopeful For Mucinex Patent Despite Initial USPTO Decision
Mucinex patent
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
Rx Guaifenesin Ban Justified By Compliance Policy Guide – Adams Labs
FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals

Topics

Advertisement
UsernamePublicRestriction

Register

PS094661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel